Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedAug 14, 2025
DataAggregated Company Financials
Companies9
  • 7D2.9%
  • 3M4.7%
  • 1Y-2.3%
  • YTD5.2%

The Pharma industry is up 2.9% in the last week, with Novartis up 5.6%. Meanwhile, BioVersys actually underperformed within the industry, shrinking 16% in the last week. The industry has been flat over the past 12 months despite the gain this week. Looking forward, earnings are forecast to grow by 13% annually.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 14 Aug 2025CHF 459.9bCHF 120.8bCHF 21.1b30.9x21.8x3.8x
Sat, 12 Jul 2025CHF 460.4bCHF 117.2bCHF 18.9b25.3x24.3x3.9x
Mon, 09 Jun 2025CHF 457.0bCHF 119.0bCHF 19.3b25.8x23.7x3.8x
Wed, 07 May 2025CHF 443.1bCHF 118.9bCHF 19.2b26.1x23.1x3.7x
Fri, 04 Apr 2025CHF 447.8bCHF 120.2bCHF 18.9b26.8x23.7x3.7x
Sun, 02 Mar 2025CHF 480.3bCHF 122.6bCHF 19.2b23.3x25.1x3.9x
Tue, 28 Jan 2025CHF 450.4bCHF 119.1bCHF 21.3b19.2x21.1x3.8x
Thu, 26 Dec 2024CHF 420.4bCHF 119.1bCHF 21.3b17.7x19.7x3.5x
Sat, 23 Nov 2024CHF 434.5bCHF 118.7bCHF 21.3b18.4x20.4x3.7x
Mon, 21 Oct 2024CHF 464.3bCHF 115.8bCHF 19.5b22x23.8x4x
Wed, 18 Sep 2024CHF 451.2bCHF 114.7bCHF 19.3b21.6x23.4x3.9x
Fri, 16 Aug 2024CHF 466.7bCHF 116.3bCHF 19.5b21.9x23.9x4x
Sun, 14 Jul 2024CHF 447.4bCHF 116.1bCHF 19.7b34.6x22.7x3.9x
Tue, 11 Jun 2024CHF 426.0bCHF 116.3bCHF 19.8b43.9x21.6x3.7x
Thu, 09 May 2024CHF 399.3bCHF 113.3bCHF 19.9b40.5x20x3.5x
Sat, 06 Apr 2024CHF 395.4bCHF 112.0bCHF 19.4b37.1x20.4x3.5x
Mon, 04 Mar 2024CHF 388.1bCHF 110.5bCHF 19.7b24.3x19.7x3.5x
Wed, 31 Jan 2024CHF 413.3bCHF 120.0bCHF 18.7b27.1x22.1x3.4x
Fri, 29 Dec 2023CHF 391.2bCHF 118.6bCHF 18.5b25.2x21.1x3.3x
Sun, 26 Nov 2023CHF 393.3bCHF 121.3bCHF 18.9b24.8x20.8x3.2x
Tue, 24 Oct 2023CHF 389.2bCHF 120.9bCHF 18.5b25.6x21x3.2x
Thu, 21 Sep 2023CHF 410.5bCHF 112.6bCHF 18.0b46.8x22.8x3.6x
Sat, 19 Aug 2023CHF 401.9bCHF 111.9bCHF 17.9b47.2x22.4x3.6x
Mon, 17 Jul 2023CHF 408.4bCHF 113.4bCHF 18.6b36.9x21.9x3.6x
Wed, 14 Jun 2023CHF 427.1bCHF 115.6bCHF 18.9b38x22.5x3.7x
Fri, 12 May 2023CHF 434.7bCHF 115.1bCHF 18.9b40.7x23x3.8x
Sun, 09 Apr 2023CHF 431.3bCHF 115.2bCHF 18.9b42.4x22.8x3.7x
Tue, 07 Mar 2023CHF 397.7bCHF 116.6bCHF 19.1b27x20.8x3.4x
Thu, 02 Feb 2023CHF 430.9bCHF 117.7bCHF 34.8b23.8x12.4x3.7x
Sat, 31 Dec 2022CHF 436.3bCHF 117.1bCHF 34.6b22.5x12.6x3.7x
Mon, 28 Nov 2022CHF 446.6bCHF 118.3bCHF 35.1b23.2x12.7x3.8x
Wed, 26 Oct 2022CHF 455.9bCHF 121.3bCHF 37.3b21.8x12.2x3.8x
Fri, 23 Sep 2022CHF 432.2bCHF 120.6bCHF 37.0b20.3x11.7x3.6x
Sun, 21 Aug 2022CHF 456.6bCHF 119.4bCHF 36.5b21.9x12.5x3.8x
Price to Earnings Ratio

12.5x


Total Market Cap: CHF 456.6bTotal Earnings: CHF 36.5bTotal Revenue: CHF 119.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 20.5x202320242025
Current Industry PE
  • Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 20.5x.
  • The industry is trading close to its 3-year average PS ratio of 3.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 17% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market1.52%
Healthcare2.44%
Pharma2.88%
Pharma2.88%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVN NovartisCHF 98.575.9%
+CHF 10.7b		-0.2%PE17.3x
ROG Roche HoldingCHF 250.100.4%
+CHF 850.3m		-11.2%PE22.6x
GALD Galderma GroupCHF 131.000.5%
+CHF 142.4m		63.3%PE102.1x
NWRN Newron PharmaceuticalsCHF 7.555.0%
+CHF 7.2m		4.6%PE10.1x
COPN Cosmo PharmaceuticalsCHF 55.900.4%
+CHF 3.2m		-28.3%PE15.8x

Latest News

NWRN
CHF 7.55
Newron Pharmaceuticals
7D
5.0%
1Y
4.6%
DESN
CHF 298.50
Dottikon ES Holding
7D
-1.2%
1Y
15.3%

Does Dottikon ES Holding (VTX:DESN) Have A Healthy Balance Sheet?

Aug 13
Does Dottikon ES Holding (VTX:DESN) Have A Healthy Balance Sheet?
SDZ
CHF 47.38
Sandoz Group
7D
-6.2%
1Y
27.1%
NOVN
CHF 98.57
Novartis
7D
5.9%
1Y
-0.2%
ROG
CHF 250.10
Roche Holding
7D
0.4%
1Y
-11.2%
COPN
CHF 55.90
Cosmo Pharmaceuticals
7D
0.4%
1Y
-28.3%
GALD
CHF 131.00
Galderma Group
7D
0.5%
1Y
63.3%
BIOV
CHF 27.30
BioVersys
7D
-2.5%
1Y
n/a
CURN
CHF 11.95
Curatis Holding
7D
-2.8%
1Y
120.5%